This is what the 10Q from last September stated:
Post# of 72440
(Total Views: 489)
Posted On: 07/30/2019 3:03:33 PM
This is what the 10Q from last September stated:
"The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement."
This is what AlfaSigma license agreement was for:
"for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis"
Sure seems like B-OM could be the next to be licensed and perhaps sooner rather than later.....but a K surprise would be fine too.....especially considering the recent article.
"The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement."
This is what AlfaSigma license agreement was for:
"for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis"
Sure seems like B-OM could be the next to be licensed and perhaps sooner rather than later.....but a K surprise would be fine too.....especially considering the recent article.
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼